Citryll

Citryll, founded in 2015 and headquartered in The Netherlands, is carving a niche in the biopharmaceutical industry with its pioneering work on the neutrophil extracellular trap (NET) pathway—a critical factor in inflammatory diseases. By leveraging their comprehensive understanding of NET biology, Citryll aims to revolutionize treatment approaches through their lead antibody, CIT-013.

The company’s focus on rheumatoid arthritis and hidradenitis suppurativa positions CIT-013 as a potentially transformative therapy, underpinning future expansions into a broader spectrum of inflammatory conditions. This strategy not only highlights their commitment but also sets the groundwork for redefining existing treatment paradigms.

Supported by a €18.50M Series B investment in 2020 from key investors including Seventure Partners, BioGeneration Ventures, and BrightGene, Citryll is well-positioned to advance its clinical ambitions. The backing underscores confidence in Citryll's potential to impact the biotechnology landscape significantly.